Skip to main content
SpringerLink
Log in

The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model

  • Protocol
  • First Online:
Urothelial Carcinoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1655))

Abstract

Urinary bladder cancer (UBC) is a common and complex malignancy, with a multifactorial etiology, like environmental factors, such as cigarette smoking, occupational exposure, and genetic factors.

UBC exhibits considerable genotypic and phenotypic heterogeneity. Among all UBC lesions, urothelial carcinoma is the most frequently observed histological type. Despite all the developments made in urologic oncology field, therapeutic options remain inadequate. There is urgency for the identification and development of new antineoplastic drugs to replace or improve current protocols and in vivo models have been proven to be essential for this step. There are different animal models of UBC: Spontaneous and experimentally induced models (genetically engineered, transplantable-xenograft and syngeneic animals- and chemically induced models). N-butyl-N(4-hydroxybutil)nitrosamine (BBN) is the most suitable reagent to generate chemically induced in vivo models of UBC and to study bladder carcinogenesis. BBN has proven, over the years, to be very realistic and reliable. It is bladder specific, and induces high tumor incidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29

    Article  PubMed  Google Scholar 

  2. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12–20

    Article  Google Scholar 

  3. Bellmunt J, Mottet N, De Santis M (2016) Urothelial carcinoma management in elderly or unfit patients. EJC Suppl 14(1):1–20

    Article  PubMed  PubMed Central  Google Scholar 

  4. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2016) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108. doi:10.1016/j.eururo.2016.06.010

    Article  PubMed  Google Scholar 

  5. Mahdavifar N, Ghoncheh M, Pakzad R, Momenimovahed Z, Salehiniya H (2016) Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world. Asian Pac J Cancer Prev 17(1):381–386

    Article  PubMed  Google Scholar 

  6. Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND (2012) Bladder cancer risk from occupational and environmental exposures. Urol Oncol 30(2):199–211

    Article  CAS  PubMed  Google Scholar 

  7. Chu H, Wang M, Zhang Z (2013) Bladder cancer epidemiology and genetic susceptibility. J Biomed Res 27:170–178

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Santos J, Chaves J, Videira M, Botelho M, Costa J, Oliveira J, Santos L (2012) Schistosomiasis haematobium and bladder cancer: retrospective analysis of 145 patients admitted to the urology. Department at the Américo Boavida Hospital, Luanda. Acta Urol 1:15–20

    Google Scholar 

  9. Kader KA (2011) Bladder cancer. Sci World J 11:2565–2566

    Article  Google Scholar 

  10. Oliveira PA, Arantes-Rodrigues R, Vasconcelos-Nóbrega C (2014) Animal models of urinary bladder cancer and their application to novel drug discovery. Expert Opin Drug Discov 9(5):485–503

    Article  CAS  PubMed  Google Scholar 

  11. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388(10061):2796–2810. doi:10.1016/S0140-6736(16)30512-8

    Article  PubMed  Google Scholar 

  12. Chalasani V, Chin JL, Izawa JI (2009) Histologic variants of urothelial bladder cancer and non urothelial histology in bladder cancer. Can Urol Assoc J 3(6Suppl4):S193–S198

    PubMed  PubMed Central  Google Scholar 

  13. Shanks JH, Iczkowski KA (2009) Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology 54(7):885–900

    Article  CAS  PubMed  Google Scholar 

  14. Anastasiadis A, de Reijke TM (2012) Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 4(1):13–32

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10(1):31–43

    PubMed  PubMed Central  Google Scholar 

  16. Grignon DJ (2009) The current classification of urothelial neoplasms. Mod Pathol 22:S60–S69

    Article  PubMed  Google Scholar 

  17. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16(11):3011–3018

    Article  CAS  PubMed  Google Scholar 

  18. Knowles MA (2007) Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 25:581–593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Noël N, Couteau J, Maillet G, Gobet F, d'Aloisio F, Minier C, Pfister C (2013) Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors. Prog Urol 23(1):29–35

    Article  PubMed  Google Scholar 

  20. Van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH (2002) Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198(2):245–251

    Article  PubMed  Google Scholar 

  21. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E (2004) Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91:2034–2041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jarow J, Maher VE, Tang S, Ibrahim A, Kim G, Sridhara R, Pazdur R (2015) Development of systemic and topical drugs to treat non-muscle invasive bladder cancer. Bl Cancer 1(2):133–136

    Article  PubMed  PubMed Central  Google Scholar 

  23. Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, Villavicencio H (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 62(1):118–125

    Article  PubMed  Google Scholar 

  24. Garcia del Muro X, Torregrosa A, Muñoz J, Castellsagué X, Condom E, Vigués F, Arance A, Fabra A, Germà JR (2000) Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer 36(3):357–362

    Article  CAS  PubMed  Google Scholar 

  25. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5(9):713–725

    Article  CAS  PubMed  Google Scholar 

  26. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22(6):1014–1024

    Article  CAS  PubMed  Google Scholar 

  27. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57(7):1217–1221

    CAS  PubMed  Google Scholar 

  28. Braasch MR, Bohle A, O’Donnell MA (2009) Intravesical instillation treatment of non–muscle-invasive bladder cancer. Eur Urol Suppl 8:549–555

    Article  Google Scholar 

  29. Rosenberg JE, Hahn WC (2009) Bladder cancer: modeling and translation. Genes Dev 23:655–659

    Article  CAS  PubMed  Google Scholar 

  30. Zips D, Thames HD, Baumann M (2005) New anticancer agents: in vitro and in vivo evaluation. In Vivo 19(1):1–7

    CAS  PubMed  Google Scholar 

  31. Van Dam D, De Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956–970

    Article  PubMed  Google Scholar 

  32. Oliveira PA, Gil da Costa RM, Vasconcelos-Nóbrega C, Arantes-Rodrigues R, Pinto-Leite R (2016) Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery. Expert Opin Drug Discov 11(6):599–607

    Article  CAS  PubMed  Google Scholar 

  33. Gil da Costa RM, Oliveira PA, Vilanova M, Bastos MM, Lopes CC, Lopes C (2011) Ptaquiloside-induced B-cell lymphoproliferative and early-stage urothelial lesions in mice. Toxicon 58:543–549

    Article  CAS  PubMed  Google Scholar 

  34. Gil da Costa RM, Bastos MMSM, Oliveira PA, Lopes C (2012) Bracken-associated human and animal health hazards: chemical, biological and pathological evidence. J Hazard Mater 203-204:1–12

    Article  CAS  PubMed  Google Scholar 

  35. Gil da Costa RM, Oliveira PA, Bastos MMSM, Lopes CC, Lopes C (2014) Ptaquiloside-induced early-stage urothelial lesions: increased cell proliferation and intact β-catenin and E-cadherin expression. Environ Toxicol 29:763–769

    Article  CAS  PubMed  Google Scholar 

  36. Knapp DW, Ramos-Vara JA, Moore GE et al (2014) Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J 55(1):100–118

    Article  CAS  PubMed  Google Scholar 

  37. Knapp DW, Waters DJ (1997) Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today 3(1):8–11

    Article  CAS  PubMed  Google Scholar 

  38. Lairmore MD, Khanna C (2014) Naturally occurring diseases in animals: contributions to translational medicine. ILAR J 55(1):1–3

    Article  CAS  PubMed  Google Scholar 

  39. Arentsen HC, Hendricksen K, Oosterwijk E, Witjes JA (2009) Experimental rat bladder urothelial cell carcinoma models. World J Urol 27(3):313–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ding J, Xu D, Pan C, Ye M, Kang J, Bai Q, Qi J (2014) Current animal models of bladder cancer: awareness of translatability (review). Exp Ther Med 8(3):691–699

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Arantes-Rodrigues R, Colaço A, Pinto-Leite R, Oliveira PA (2013) In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res 33(4):1273–1296

    CAS  PubMed  Google Scholar 

  42. Rosenbert MP, Bortner D (1998) Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev 17:295–299

    Article  Google Scholar 

  43. Russell PJ, Raghavan D, Gregory P et al (1986) Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res 46:2035–2040

    CAS  PubMed  Google Scholar 

  44. Günther JH, Jurczok A, Wulf T et al (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59:2834–2837

    PubMed  Google Scholar 

  45. Chan ESY, Patel AR, Smith AK et al (2009) Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol 183(6):2926–2931

    Article  Google Scholar 

  46. Oliveira PA, Colaço A, De la Cruz Palomino LF, Lopes C (2006) Experimental bladder carcinogenesis–rodent models. Exp Oncol 28:2–11

    CAS  PubMed  Google Scholar 

  47. Gil da Costa RM, Oliveira PA, Vasconcelos-Nóbrega C, Arantes-Rodrigues R, Pinto-Leite R, Colaço A, de la Cruz PLF, Lopes C (2015) Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis. Int J Exp Pathol 96(5):319–325. doi:10.1111/iep.12145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cohen SM (1983) Promotion in urinary bladder carcinogenesis. Environ Health Perspect 50:51–59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Johansson SL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13:291–298

    Article  CAS  PubMed  Google Scholar 

  50. Cohen SM (2008) Tresholds in genotoxicity and carcinogenicity: urinary bladder carcinogenesis. Genes Environ 30(4):132–138

    Article  CAS  Google Scholar 

  51. Jiang T, Lui T, Li L, Yang Z, Bai Y, Liu D, Kong C (2016) Knockout of phospholipase Cε attenuates N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumorigenesis. Mol Med Rep 13:2039–2045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bonfanti M, Magagnotti C, Bonati M, Fanelli R, Airoldi L (1988) Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res 48:3666–3669

    CAS  PubMed  Google Scholar 

  53. Mirvish SS (1995) Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 93:17–48

    Article  CAS  PubMed  Google Scholar 

  54. Iida K, Itoh K, Maher JM, Kumagai Y, Oyasu R, Mori Y, Shimazui T, Akaza H, Yamamoto M (2007) Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis 28(11):2398–2403

    Article  CAS  PubMed  Google Scholar 

  55. Suzuki E, Okada M (1980) Metabolic fate of N-butyl-N-(4-hydroxybutyl)nitrosamine in the rat. Gann 71(6):856–862

    CAS  PubMed  Google Scholar 

  56. Mochizuki M, Suzuki E, Okada M (1997) Structure and metabolic fate of N-nitrosodialkylamines in relation to their organotropic carcinogenicity with special reference to induction of urinary bladder tumors. Yakugaku Zasshi 117(10-11):884–894

    Article  CAS  PubMed  Google Scholar 

  57. Cohen SM (1998) Urinary bladder carcinogenesis. Toxicol Pathol 26:121–127

    Article  CAS  PubMed  Google Scholar 

  58. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL (2007) Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol 35(3):337–347

    Article  CAS  PubMed  Google Scholar 

  59. Okada M, Suzuki E, Hashimoto Y (1976) Carcinogenicity of N-nitrosamines related to N-butyl-N-(4-Hydroxybutyl)nitrosamine and N, N-Dibutylnitrosamine in ACI/N rats. Gann 67:825–834

    CAS  PubMed  Google Scholar 

  60. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R (1987) Development of an experimental model for studying bladder carcinogen metabolism using the isolated rat urinary bladder. Cancer Res 47:3697–3700

    CAS  PubMed  Google Scholar 

  61. Yamamoto K, Nakata D, Tada M, Tonoki H, Nishida T, Hirai A, Ba Y, Aoyama T, Hamada J, Furuuchi K, Harada H, Hirai K, Shibahara N, Katsuoka Y, Moriuchi T (1999) A functional and quantitative mutational analysis of p53 mutations in yeast indicates strand biases and different roles of mutations in DMBA- and BBN-induced tumors in rats. Int J Cancer 83:700–705

    Article  CAS  PubMed  Google Scholar 

  62. Weisburger JH, Williams GM (2000) The distinction between genotoxic and epigenetic carcinogens and implication for cancer risk. Toxicol Sci 57:4–5

    Article  CAS  PubMed  Google Scholar 

  63. Drago JR (2004) The noble rat bladder cancer model–FANFT induced Tumours. Cancer 53:1093–1099

    Article  Google Scholar 

  64. Mann AM, Asamoto M, Chlapowski FJ, Masui T, Macatee TL, Cohen SM (1992) Ras involvement in cells transformed with 2-amino-4-(5-nitro-2-furyl)thiazole (ANFT) in vitro and with N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide in vivo. Carcinogenesis 13(9):1651–1655

    Article  CAS  PubMed  Google Scholar 

  65. Reis LO, Pereira TC, Favaro WJ, Cagnon VH, Lopes-Cendes I, Ferreira U (2009) Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 27:353

    Article  CAS  PubMed  Google Scholar 

  66. Spry LA, Rubinstein J, Rettke C, Zenser TV, Davis BB (1988) Renal metabolic/excretory coupling. Am J Physiol 254(1):F145–F152

    CAS  PubMed  Google Scholar 

  67. Severs NJ, Barnes SH, Wright R, Hicks RM (1982) Induction of bladder cancer in rats by fractionated intravesicular doses of N-methyl-N-nitrosourea. Br J Cancer 45:337–351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Steinberg GD, Brendler CB, Ichikawa T, Squire RA, Isaacs JT (1990) Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res 50(20):6668–6674

    CAS  PubMed  Google Scholar 

  69. Vasconcelos-Nóbrega C, Colaço A, Lopes C, Oliveira PA (2012) Review: BBN as an urothelial carcinogen. In Vivo 26(4):727–739

    PubMed  Google Scholar 

  70. Cohen SM, Friedell GH (1982) Neoplasms of the urinary system. In: The mouse in biomedical research. Academic Press, New York, pp 439–463

    Google Scholar 

  71. Ito N, Shirai T, Fukushima S, Hirose M (1984) Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. J Cancer Res Clin Oncol 108:169–173

    Article  CAS  PubMed  Google Scholar 

  72. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, Niijima T (1986) Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 46:2011–2004

    Google Scholar 

  73. Wanibuchi H, Wei M, Salim EI, Kinoshita A, Morimura K, Sudo K, Fukushima S (2006) Inhibition of rat urinary bladder carcinogenesis by the antiangiogenic drug TNP-470. Asian Pac J Cancer Prev 7:101–107

    PubMed  Google Scholar 

  74. Wang SC, Huang CC, Shen CH, Lin LC, Zhao PW, Chen SY, Deng YC, Liu YW (2016) Gene expression and DNA methylationstatus of glutathione-S-transferase Mu1 and Mu5 in urothelial carcinoma. PLoS One 11:e0159102

    Article  PubMed  PubMed Central  Google Scholar 

  75. Oliveira PA, Palmeira C, Lourenço L, Lopes C (2005) Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Exp Clin Cancer Res 24:207–214

    Google Scholar 

  76. Arantes-Rodrigues R, Henriques A, Pinto-Leite R, Faustino-Rocha A, Pinho-Oliveira J, Teixeira-Guedes C, Seixas F, Gama A, Colaço B, Colaço A, Oliveira PA (2012) The effects of repeated oral gavage on the health of male CD-1 mice. Lab Anim (NY) 41(5):129–134

    Article  Google Scholar 

  77. Okada M, Ishidate M (1977) Metabolic fate of N-butyl-N-(4-hydroxybutyl)-nitrosamine and its analogues: selective induction of urinary bladder tumours in the rat. Xenobiotica 7(1):11–24

    Article  CAS  PubMed  Google Scholar 

  78. Hashimoto Y, Suzuki K, Okada M (1974) Induction of urinary bladder tumors by intravesicular instillation of butyl(4-hydroxybutyl)nitrosoamine and its principal urinary metabolite, butyl(3-carboxypropyl)nitrosoamine in rats. Gann 65:69–73

    CAS  PubMed  Google Scholar 

  79. Fuji K, Odashima S, Okada M (1977) Induction of tumours by administration of N-dibutylnitrosamine and derivatives to infant mice. Br J Cancer 35:610–614

    Article  Google Scholar 

  80. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shirai T, Ito N (1977) Damage and repair of DNA in urinary bladder epithelium of rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann 68:781–783

    CAS  PubMed  Google Scholar 

  81. Oliveira PA, Pires MJ, Nóbrega C, Arantes-Rodrigues R, Calado AM, Carrola J, Ginja M, Colaço A (2009) Technical report: technique of bladder catheterization in female mice and rats for intravesical instillation in models of bladder cancer. Scand J Lab Anim Sci 36(1):5–9

    CAS  Google Scholar 

  82. Xu J, Wang Y, Hua X, Xu J, Tian Z, Jin H, Li J, Wu XR, Huang C (2016) Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100). Oncotarget 7:34112–34130

    PubMed  PubMed Central  Google Scholar 

  83. Suzuki E, Anjo T, Aoki J, Okada M (1983) Species variations in the metabolism of N-butyl-N-(4-hydroxybutyl)nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Gann 74:60–68

    CAS  PubMed  Google Scholar 

  84. Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, Beachy PA (2014) Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 16:469–478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Van Loo PLP, Kruitwagenb CLJJ, Koolhaasc JM, Van de Weerdd HA, Van Zutphena LFM, Baumansa V (2002) Influence of cage enrichment on aggressive behaviour and physiological parameters in male mice. Appl Anim Behav Sci 76:65–81

    Article  Google Scholar 

  86. Danneman PJ, Suckow MA, Brayton CF (2012) The laboratory mouse, 2nd edn. Taylor and Francis, London

    Google Scholar 

  87. Conn PM (2013) Animal models for the study of human disease, 1st edn. Elsevier, Amsterdam

    Google Scholar 

  88. Wolfer DP, Litvin O, Morf S, Nitsch RM, Lipp HP, Würbel H (2004) Laboratory animal welfare: cage enrichment and mouse behaviour. Nature 432:821–822

    Article  CAS  PubMed  Google Scholar 

  89. Gouveia K, Hurst JL (2013) Reducing mouse anxiety during handling: effect of experience with handling tunnels. PLoS One 8:e66401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal

    Paula A. Oliveira, Rui M. Gil da Costa & Regina Arantes-Rodrigues

  2. Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Vila Real, Portugal

    Paula A. Oliveira, Rui M. Gil da Costa & Regina Arantes-Rodrigues

  3. Centre for the Study of Education, Technologies and Health, Polythecnic Institute of Viseu, Viseu, Portugal

    Cármen Vasconcelos-Nóbrega

Authors
  1. Paula A. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cármen Vasconcelos-Nóbrega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui M. Gil da Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Regina Arantes-Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula A. Oliveira .

Editor information

Editors and Affiliations

  1. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Wolfgang A Schulz

  2. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Michèle J. Hoffmann

  3. Department of Urology, Heinrich Heine University, Düsseldorf, Germany

    Günter Niegisch

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Oliveira, P.A., Vasconcelos-Nóbrega, C., Gil da Costa, R.M., Arantes-Rodrigues, R. (2018). The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model. In: Schulz, W., Hoffmann, M., Niegisch, G. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 1655. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7234-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7234-0_13

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7233-3

  • Online ISBN: 978-1-4939-7234-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation